Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.
Mateza S, Bradford Y, Maartens G, Sokhela S, Chandiwana NC, Venter WDF, Post FA, Ritchie MD, Haas DW, Sinxadi P. Mateza S, et al. Among authors: post fa. Pharmacogenet Genomics. 2023 Jul 1;33(5):91-100. doi: 10.1097/FPC.0000000000000491. Epub 2023 Apr 24. Pharmacogenet Genomics. 2023. PMID: 37099271 Free PMC article. Clinical Trial.
The Evolving Spectrum of Kidney Histology in HIV-Positive Patients in South Africa.
Wearne N, Manning K, Price B, Rayner BL, Davidson B, Jones ES, Spies R, Cunningham C, Omar A, Ash S, Bohmer R, Kennedy L, Post F. Wearne N, et al. Kidney Int Rep. 2023 Feb 23;8(5):1087-1096. doi: 10.1016/j.ekir.2023.02.1076. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180521 Free PMC article.
Integration of High-Throughput Imaging and Multiparametric Metabolic Profiling Reveals a Mitochondrial Mechanism of Tenofovir Toxicity.
Pearson A, Haenni D, Bouitbir J, Hunt M, Payne BAI, Sachdeva A, Hung RKY, Post FA, Connolly J, Nlandu-Khodo S, Jankovic N, Bugarski M, Hall AM. Pearson A, et al. Among authors: post fa. Function (Oxf). 2022 Dec 24;4(1):zqac065. doi: 10.1093/function/zqac065. eCollection 2023. Function (Oxf). 2022. PMID: 36654930 Free PMC article.
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction-associated fatty liver disease(MAFLD) in adults with suppressed HIV.
Mccabe L, Burns JE, Latifoltojar A, Post FA, Fox J, Pool E, Waters A, Santana B, Garvey L, Johnson M, Mcguinness I, Chouhan M, Edwards J, Goodman AL, Cooke G, Murphy C, Collaco-Moraes Y, Webb H, Gregory A, Mohamed F, Rauchenberger M, Ryder SD, Sandford C, Baker JV, Angus B, Boesecke C, Orkin C, Punwani S, Clark A, Gilson R, Dunn D, Pett SL; MAVMET Study group. Mccabe L, et al. Among authors: post fa. AIDS. 2024 May 31. doi: 10.1097/QAD.0000000000003947. Online ahead of print. AIDS. 2024. PMID: 38819839
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Among authors: post fa. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
191 results